A study of two osteoporosis drugs has shown that they reduce the risk of fractures, it has been announced.
Fosamax and Reclast were assessed as part of a study published by the New England Journal of Medicine, after concerns had been raised that the drugs may actually be causing unusual fractures of the upper thigh bone.
"Many more common and equally devastating hip fractures are prevented by bisphosphonates than are potentially caused by the drugs," stated Dr Elizabeth Shane of Columbia University, writing in the journal's editorial.
The study's leader, Dr Dennis Black of the University of California, San Francisco, commented: "If we treated 1,000 osteoporotic women for three years, we estimate you would prevent 100 fractures."
Over such a treatment period, it is suggested that perhaps one or fewer of the unusual thigh fractures may occur.
According to the NHS, approximately three million people in the UK have osteoporosis and there are 230,000 fractures every year as a result of the condition.
Serious Law, leading spinal cord injury solicitors
